{"url_path":"/sec/mrvi/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1823239/0001823239-26-000024-index.html","accession_number":"0001823239-26-000024","cik":"0001823239","ticker":"MRVI","issuer_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1823239/0001823239-26-000024-index.html","primary_entity_key":"0001823239","primary_entity_name":"MARAVAI LIFESCIENCES HOLDINGS, INC."},"word_count":117,"has_tables":true,"body_markdown":"Item 5. Other Information\n\nInsider Trading Arrangements\n\nOn March 10, 2026, Kurt Oreshack, our Executive Vice President, General Counsel and Secretary, adopted a Rule 10b5-1 trading plan that is intended to satisfy the affirmative defense Rule 10b5-1(c) for the sale of up to 50,000 shares of the Company’s Class A common stock prior to the expiration of the plan on August 10, 2026.\n\nDuring the three months ended March 31, 2026, none of the Company’s other directors or officers (as defined in Section 16 of the Exchange Act) adopted or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement” (each as defined in Item 408(a) and (c) of Regulation S-K).\n\n37\n\n[Table of Contents](#ied43387d9d824ef292825d07e284e584_7)"}